Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Am J Psychiatry ; 179(2): 132-141, 2022 Feb.
Article in English | MEDLINE | ID: mdl-34711062

ABSTRACT

OBJECTIVE: Depression is the leading cause of disability worldwide, and half of patients with depression have treatment-resistant depression. Intermittent theta-burst stimulation (iTBS) is approved by the U.S. Food and Drug Administration for the treatment of treatment-resistant depression but is limited by suboptimal efficacy and a 6-week duration. The authors addressed these limitations by developing a neuroscience-informed accelerated iTBS protocol, Stanford neuromodulation therapy (SNT; previously referred to as Stanford accelerated intelligent neuromodulation therapy, or SAINT). This protocol was associated with a remission rate of ∼90% after 5 days of open-label treatment. Here, the authors report the results of a sham-controlled double-blind trial of SNT for treatment-resistant depression. METHODS: Participants with treatment-resistant depression currently experiencing moderate to severe depressive episodes were randomly assigned to receive active or sham SNT. Resting-state functional MRI was used to individually target the region of the left dorsolateral prefrontal cortex most functionally anticorrelated with the subgenual anterior cingulate cortex. The primary outcome was score on the Montgomery-Åsberg Depression Rating Scale (MADRS) 4 weeks after treatment. RESULTS: At the planned interim analysis, 32 participants with treatment-resistant depression had been enrolled, and 29 participants who continued to meet inclusion criteria received either active (N=14) or sham (N=15) SNT. The mean percent reduction from baseline in MADRS score 4 weeks after treatment was 52.5% in the active treatment group and 11.1% in the sham treatment group. CONCLUSIONS: SNT, a high-dose iTBS protocol with functional-connectivity-guided targeting, was more effective than sham stimulation for treatment-resistant depression. Further trials are needed to determine SNT's durability and to compare it with other treatments.


Subject(s)
Depressive Disorder, Treatment-Resistant , Transcranial Magnetic Stimulation , Depressive Disorder, Treatment-Resistant/therapy , Double-Blind Method , Gyrus Cinguli , Humans , Prefrontal Cortex , Transcranial Magnetic Stimulation/methods , Treatment Outcome
3.
Am J Psychiatry ; 177(8): 716-726, 2020 08 01.
Article in English | MEDLINE | ID: mdl-32252538

ABSTRACT

OBJECTIVE: New antidepressant treatments are needed that are effective, rapid acting, safe, and tolerable. Intermittent theta-burst stimulation (iTBS) is a noninvasive brain stimulation treatment that has been approved by the U.S. Food and Drug Administration for treatment-resistant depression. Recent methodological advances suggest that the current iTBS protocol might be improved through 1) treating patients with multiple sessions per day at optimally spaced intervals, 2) applying a higher overall pulse dose of stimulation, and 3) precision targeting of the left dorsolateral prefrontal cortex (DLPFC) to subgenual anterior cingulate cortex (sgACC) circuit. The authors examined the feasibility, tolerability, and preliminary efficacy of Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT), an accelerated, high-dose resting-state functional connectivity MRI (fcMRI)-guided iTBS protocol for treatment-resistant depression. METHODS: Twenty-two participants with treatment-resistant depression received open-label SAINT. fcMRI was used to individually target the region of the left DLPFC most anticorrelated with sgACC in each participant. Fifty iTBS sessions (1,800 pulses per session, 50-minute intersession interval) were delivered as 10 daily sessions over 5 consecutive days at 90% resting motor threshold (adjusted for cortical depth). Neuropsychological testing was conducted before and after SAINT. RESULTS: One participant withdrew, leaving a sample size of 21. Nineteen of 21 participants (90.5%) met remission criteria (defined as a score <11 on the Montgomery-Åsberg Depression Rating Scale). In the intent-to-treat analysis, 19 of 22 participants (86.4%) met remission criteria. Neuropsychological testing demonstrated no negative cognitive side effects. CONCLUSIONS: SAINT, an accelerated, high-dose, iTBS protocol with fcMRI-guided targeting, was well tolerated and safe. Double-blinded sham-controlled trials are needed to confirm the remission rate observed in this initial study.


Subject(s)
Depressive Disorder, Treatment-Resistant , Gyrus Cinguli/physiopathology , Prefrontal Cortex/physiopathology , Transcranial Magnetic Stimulation/methods , Adult , Clinical Protocols , Cognition , Depressive Disorder, Treatment-Resistant/diagnosis , Depressive Disorder, Treatment-Resistant/physiopathology , Depressive Disorder, Treatment-Resistant/therapy , Female , Functional Neuroimaging/methods , Humans , Magnetic Resonance Imaging/methods , Male , Monitoring, Physiologic/methods , Neuropsychological Tests , Psychiatric Status Rating Scales , Remission Induction/methods
4.
Mol Psychiatry ; 24(12): 1779-1786, 2019 12.
Article in English | MEDLINE | ID: mdl-31467392

ABSTRACT

We recently reported that naltrexone blocks antidepressant effects of ketamine in humans, indicating that antidepressant effects of ketamine require opioid receptor activation. However, it is unknown if opioid receptors are also involved in ketamine's antisuicidality effects. Here, in a secondary analysis of our recent clinical trial, we test whether naltrexone attenuates antisuicidality effects of ketamine. Participants were pretreated with naltrexone or placebo prior to intravenous ketamine in a double-blinded crossover design. Suicidality was measured with the Hamilton Depression Rating Scale item 3, Montgomery-Åsberg Depression Rating Scale item 10, and Columbia Suicide Severity Rating Scale. In the 12 participants who completed naltrexone and placebo conditions, naltrexone attenuated the antisuicidality effects of ketamine on all three suicidality scales/subscales (linear mixed model, fixed pretreatment effect, p < 0.01). Results indicate that opioid receptor activation plays a significant role in the antisuicidality effects of ketamine.


Subject(s)
Ketamine/therapeutic use , Narcotic Antagonists/metabolism , Receptors, Opioid/metabolism , Adult , Antidepressive Agents/therapeutic use , Cross-Over Studies , Depressive Disorder, Treatment-Resistant/drug therapy , Double-Blind Method , Excitatory Amino Acid Antagonists/therapeutic use , Female , Humans , Ketamine/metabolism , Male , Middle Aged , Naltrexone/pharmacology , Psychiatric Status Rating Scales , Suicidal Ideation , Suicide/psychology , Treatment Outcome
6.
Front Aging Neurosci ; 6: 153, 2014.
Article in English | MEDLINE | ID: mdl-25071562

ABSTRACT

Separate bodies of literature report that elevated pro-inflammatory cytokines and cortisol negatively affect hippocampal structure and cognitive functioning, particularly in older adults. Although interactions between cytokines and cortisol occur through a variety of known mechanisms, few studies consider how their interactions affect brain structure. In this preliminary study, we assess the impact of interactions between circulating levels of IL-1Beta, IL-6, IL-8, IL-10, IL-12, TNF-alpha, and waking cortisol on hippocampal volume. Twenty-eight community-dwelling older adults underwent blood draws for quantification of circulating cytokines and saliva collections to quantify the cortisol awakening response. Hippocampal volume measurements were made using structural magnetic resonance imaging. Elevated levels of waking cortisol in conjunction with higher concentrations of IL-6 and TNF-alpha were associated with smaller hippocampal volumes. In addition, independent of cortisol, higher levels of IL-1beta and TNF-alpha were also associated with smaller hippocampal volumes. These data provide preliminary evidence that higher cortisol, in conjunction with higher IL-6 and TNF-alpha, are associated with smaller hippocampal volume in older adults. We suggest that the dynamic balance between the hypothalamic-pituitary adrenal axis and inflammation processes may explain hippocampal volume reductions in older adults better than either set of measures do in isolation.

7.
Neuropsychopharmacology ; 38(5): 826-45, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23303057

ABSTRACT

The glucocorticoid hormone cortisol is known to have wide-ranging effects on a variety of physiological systems, including the morphology and physiology of the amygdala and hippocampus. Disruptions of cortisol regulation and signaling are also linked with psychiatric disorders involving emotional disturbances. Although there is much evidence to suggest a relationship between cortisol signaling and the brain physiology underlying emotion, few studies have attempted to test for direct effects of cortisol on the neurophysiology of emotion. We administered exogenous synthetic cortisol (hydrocortisone, HCT) using two different dosing regimens (25 mg/day over 4 days, 100 mg single dose), in a double-blind placebo-controlled functional magnetic resonance imaging (fMRI) study. During fMRI scanning, healthy subjects viewed images designed to induce happy, sad, and neutral emotional states. Subjective emotional reactions were collected for each experimental stimulus after fMRI scanning. Mood ratings were also collected throughout the 4 days of the study. Both dose regimens of HCT resulted in decreased subgenual cingulate activation during sadness conditions. The 25 mg/day regimen also resulted in higher arousal ratings of sad stimuli. No effects of HCT were observed on any mood ratings. Few reliable effects of HCT were observed on brain activity patterns or subjective emotional responses to stimuli that were not sad. The inhibitory effects of cortisol on sadness-induced subgenual cingulate activity may have critical relevance to the pathophysiology of major depression, as both subgenual hyperactivity and decreased sensitivity to cortisol signaling have been documented in patients with depression.


Subject(s)
Amygdala/drug effects , Anti-Inflammatory Agents/pharmacology , Emotions/physiology , Gyrus Cinguli/drug effects , Hydrocortisone/pharmacology , Adolescent , Adult , Amygdala/blood supply , Analysis of Variance , Brain Mapping , Case-Control Studies , Double-Blind Method , Emotions/radiation effects , Female , Gyrus Cinguli/blood supply , Humans , Hydrocortisone/metabolism , Image Processing, Computer-Assisted , Magnetic Resonance Imaging , Male , Oxygen , Psychiatric Status Rating Scales , Saliva/metabolism , Young Adult
8.
Neuroimage ; 31(2): 906-19, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16488159

ABSTRACT

Neuroimaging studies investigating emotion have commonly used two different visual stimulus formats, facial expressions of emotion or emotionally evocative scenes. However, it remains an important unanswered question whether or not these different stimulus formats entail the same processes. Facial expressions of emotion may elicit more emotion recognition/perception, and evocative pictures may elicit more direct experience of emotion. In spite of these differences, common areas of activation have been reported across different studies, but little work has investigated activations in response to the two stimulus formats in the same subjects. In this fMRI study, we compared BOLD activation patterns to facial expression of emotions and to complex emotional pictures from the International Affective Picture System (IAPS) to determine if these stimuli would activate similar or distinct brain regions. Healthy volunteers passively viewed blocks of expressive faces and IAPS pictures balanced for specific emotion (happy, sad, anger, fear, neutral), interleaved with blocks of fixation. Eye movement, reaction times, and off-line subjective ratings including discrete emotion, valence, and arousal were also recorded. Both faces and IAPS pictures activated similar structures, including the amygdala, posterior hippocampus, ventromedial prefrontal cortex, and visual cortex. In addition, expressive faces uniquely activated the superior temporal gyrus, insula, and anterior cingulate more than IAPS pictures, despite the faces being less arousing. For the most part, these regions were activated in response to all specific emotions; however, some regions responded only to a subset.


Subject(s)
Affect , Brain Mapping/methods , Facial Expression , Nerve Net/physiology , Adult , Anger , Arousal , Brain/anatomy & histology , Brain/physiology , Emotions , Fear , Female , Fixation, Ocular , Happiness , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Reference Values
9.
Anat Rec ; 268(4): 411-29, 2002 Dec 01.
Article in English | MEDLINE | ID: mdl-12420290

ABSTRACT

In this study, magnetic resonance (MR) images of the brain of an adult common dolphin (Delphinus delphis) were acquired in the coronal plane at 66 antero-posterior levels. From these scans a computer-generated set of resectioned virtual images in orthogonal planes was constructed using the programs VoxelView and VoxelMath (Vital Images, Inc., Michigan State Univ.). Sections in all three planes reveal major neuroanatomical structures. These structures in the adult common dolphin brain are compared with those from a fetal common dolphin brain from a previously published study as well as with MR images of adult brains of other odontocetes. This study, like previous ones, demonstrates the utility of MR imaging (MRI) for comparative neuroanatomical investigations of dolphin brains.


Subject(s)
Brain/anatomy & histology , Dolphins/anatomy & histology , Imaging, Three-Dimensional , Magnetic Resonance Imaging/methods , Anatomy, Cross-Sectional , Animals , Female , Organ Size , Pregnancy
SELECTION OF CITATIONS
SEARCH DETAIL
...